400 related articles for article (PubMed ID: 29370898)
1. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab.
Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A
J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898
[TBL] [Abstract][Full Text] [Related]
2. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study.
Lightner AL; Mathis KL; Tse CS; Pemberton JH; Shen B; Kochhar G; Singh A; Dulai PS; Eisenstein S; Sandborn WJ; Parry L; Stringfield S; Hudesman D; Remzi F; Loftus EV
Inflamm Bowel Dis; 2018 Mar; 24(4):871-876. PubMed ID: 29509927
[TBL] [Abstract][Full Text] [Related]
3. Postoperative outcomes in vedolizumab-treated pediatric patients undergoing abdominal operations for inflammatory bowel disease.
Lightner AL; Tse CS; Potter DD; Moir C
J Pediatr Surg; 2018 Sep; 53(9):1706-1709. PubMed ID: 29111083
[TBL] [Abstract][Full Text] [Related]
4. High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)
Ylisaukko-Oja T; Aaltonen J; Nuutinen H; Blomster T; Jussila A; Pajala M; Salminen K; Moilanen V; Hakala K; Kellokumpu M; Toljamo K; Rautiainen H; Kuisma J; Peräaho M; Molander P; Silvennoinen J; Liukkonen V; Henricson H; Tillonen J; Esterinen M; Nielsen C; Hirsi E; Lääne M; Suhonen UM; Vihriälä I; Mäkelä P; Puhto M; Punkkinen J; Sulonen H; Herrala S; Jokelainen J; Tamminen K; Sipponen T
Scand J Gastroenterol; 2018 Feb; 53(2):158-167. PubMed ID: 29258369
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease.
Lightner AL; Raffals LE; Mathis KL; Cima RR; Tse CS; Pemberton JH; Dozois EJ; Loftus EV
J Crohns Colitis; 2017 Feb; 11(2):185-190. PubMed ID: 27543504
[TBL] [Abstract][Full Text] [Related]
6. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.
Lightner AL; McKenna NP; Moncrief S; Pemberton JH; Raffals LE; Mathis KL
Inflamm Bowel Dis; 2017 Dec; 23(12):2197-2201. PubMed ID: 28858072
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-Analysis: Preoperative Vedolizumab and Postoperative Complications in Patients with IBD.
Moosvi Z; Duong JT; Bechtold ML; Nguyen DL
South Med J; 2021 Feb; 114(2):98-105. PubMed ID: 33537791
[TBL] [Abstract][Full Text] [Related]
8. Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.
Singh N; Rabizadeh S; Jossen J; Pittman N; Check M; Hashemi G; Phan BL; Hyams JS; Dubinsky MC
Inflamm Bowel Dis; 2016 Sep; 22(9):2121-6. PubMed ID: 27542130
[TBL] [Abstract][Full Text] [Related]
9. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
Battat R; Ma C; Jairath V; Khanna R; Feagan BG
Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
[TBL] [Abstract][Full Text] [Related]
10. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice.
Vivio EE; Kanuri N; Gilbertsen JJ; Monroe K; Dey N; Chen CH; Gutierrez AM; Ciorba MA
J Crohns Colitis; 2016 Apr; 10(4):402-9. PubMed ID: 26681763
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
13. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.
Koliani-Pace JL; Singh S; Luo M; Hirten R; Aniwan S; Kochhar G; Chang S; Lukin D; Gao Y; Bohm M; Swaminath A; Gupta N; Shmidt E; Meserve J; Winters A; Chablaney S; Faleck DM; Yang J; Huang Z; Boland BS; Shashi P; Weiss A; Hudesman D; Varma S; Fischer M; Sultan K; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Sandborn WJ; Lasch K; Siegel CA; Dulai PS
Inflamm Bowel Dis; 2019 Oct; 25(11):1854-1861. PubMed ID: 31050734
[TBL] [Abstract][Full Text] [Related]
14. Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study.
Amiot A; Serrero M; Peyrin-Biroulet L; Filippi J; Pariente B; Roblin X; Buisson A; Stefanescu C; Trang-Poisson C; Altwegg R; Marteau P; Vaysse T; Bourrier A; Nancey S; Laharie D; Allez M; Savoye G; Moreau J; Vuitton L; Viennot S; Bouguen G; Abitbol V; Fumery M; Gagniere C; Bouhnik Y;
Aliment Pharmacol Ther; 2019 Jul; 50(1):40-53. PubMed ID: 31165509
[TBL] [Abstract][Full Text] [Related]
15. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF biologic therapy does not increase postoperative morbidity in pediatric Crohn's patients.
Lightner AL; McKenna NP; Alsughayer A; Loftus EV; Raffals LE; Faubion WA; Moir C
J Pediatr Surg; 2019 Oct; 54(10):2162-2165. PubMed ID: 30773391
[TBL] [Abstract][Full Text] [Related]
17. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
18. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
19. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
20. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study.
Kim JY; Zaghiyan K; Lightner A; Fleshner P
BMC Surg; 2020 Mar; 20(1):46. PubMed ID: 32138717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
